VEGFR-2, is the primary receptor mediating VEGF-driven angiogenesis. Its activation promotes endothelial cell proliferation, migration, and survival. By inhibiting VEGFR-2, ramucirumab suppresses tumor vascularization and growth, and is often used in combination with chemotherapy in advanced or metastatic settings.